FDA Approves Tirzepatide for Treating Obstructive Sleep Apnea in Adults with Obesity
The U.S. Food and Drug Administration (FDA) has approved Zepbound (Tirzepatide), a weight loss medication as the first prescription treatment specifically for obstructive sleep apnea (OSA) in adults with obesity.
Continue readingFDA Approves Tirzepatide for Treating Obstructive Sleep Apnea in Adults with Obesity